AHK-Cu dosage ranges from 0.5 to 2 mg per injection in most research protocols, but no FDA-approved human dose exists. See charts, timing, and safety notes.
There is no officially established human dosage for AHK-Cu. In the research and vendor protocols most often shared online, an AHK-Cu peptide injection dosage falls between roughly 0.5 mg and 2 mg per day or every other day, with 1 mg being the most commonly cited amount. Topical cosmetic formulas typically list 1% to 2% AHK-Cu instead.
Treat that range as a description of what people discuss, not a medical recommendation. No human clinical trial has established a safe or effective AHK-Cu dosage, and the peptide is sold for laboratory research only.
What Is AHK-Cu and How Does It Compare With GHK-Cu?
If you are still asking what is ahk-cu peptide, the short answer is that it is a synthetic copper tripeptide made of alanine, histidine, and lysine bound to a copper ion. It is a close chemical relative of GHK-Cu, the better-known copper peptide, with a single amino acid swapped out.
Both peptides are studied in laboratory and animal models for collagen signaling, skin remodeling, and wound repair. Neither one is approved as a prescription drug in the United States.
| Feature | AHK-Cu | GHK-Cu |
|---|---|---|
| Amino acid sequence | Alanine-His-Lys + copper | Glycine-His-Lys + copper |
| Commonly cited research injection dose | 0.5–2 mg per day | 1–2 mg per day |
| Typical topical concentration | 1%–2% | 1%–2% |
| Human clinical trials | None for injectable use | Limited, mostly topical |
| FDA approval | Not approved | Not approved |
Much of the online debate, including ahk cu vs ghk cu reddit threads, centers on whether the alanine substitution makes AHK-Cu more stable or more potent. Marketing pages often claim it does, but peer-reviewed human data does not settle the question.
AHK-Cu Peptide Injection Dosage Ranges Used in Research
The numbers below come from published copper peptide research, vendor protocols, and user reports. They describe the spread of what is discussed, not an approved schedule.
| Route | Commonly cited amount | Frequency | Notes |
|---|---|---|---|
| Subcutaneous injection (research) | 0.5–2 mg | Daily to every other day | 1 mg is the most frequently cited figure |
| Topical serum or cream | 1%–2% concentration | Once or twice daily | Cosmetic use, not injectable |
| Low-end research protocols | 0.25–0.5 mg | Every other day | Often used by people testing tolerance |
Several variables shift where a person lands inside that range:
- Body weight: larger bodies are often assigned higher amounts in informal protocols.
- Goal: skin and hair research usually cites lower amounts than wound-repair models.
- Cycle length: most protocols run 4 to 8 weeks, then pause.
- Tolerance: injection site reactions are the most common reason people reduce the amount.
An AHK-Cu peptide injection dosage chart is only useful if it matches the concentration in your specific vial. Two vials labeled 50 mg can deliver very different amounts per unit if they were reconstituted with different volumes of water.
AHK-Cu Injection Protocol: Reconstitution and Timing
Reconstitution math
Reconstituting a 50 mg AHK-Cu vial with 5 mL of bacteriostatic water produces a 10 mg/mL solution. On a U-100 insulin syringe, 10 units (0.1 mL) of that solution equals 1 mg of peptide. Doubling the water volume halves the concentration, so always confirm your own math before drawing a dose.
Frequency and cycle length
- Most protocols use one injection per day or every other day.
- Typical cycles last 4 to 8 weeks, followed by a 2 to 4 week break.
- Subcutaneous injections are usually placed in the abdomen or thigh, rotating sites each time.
- Refrigerate reconstituted vials and protect them from light.
Because the peptide is not approved for human use, no manufacturer publishes an official injection schedule, and any protocol you find online is somebody's interpretation rather than a validated standard.
Topical AHK-Cu Dosage for Skin and Hair
In cosmetics, AHK-Cu appears at 1% to 2% in serums, creams, and scalp treatments. That is a concentration, not a milligram dose, and it is applied to the skin rather than injected.
Comparing ahk-cu vs minoxidil is common because both are discussed for hair thinning, but the two are not interchangeable. Minoxidil is an FDA-approved topical treatment with large clinical trials behind it; AHK-Cu has no equivalent human evidence for hair regrowth.
Copper peptides are generally considered well tolerated on intact skin. Irritation, redness, and itching are the reactions most often reported, and broken or freshly treated skin can sting.
Safety, Side Effects, and Legal Status
AHK-Cu is not FDA-approved for human use in the United States. It cannot legally be sold as a dietary supplement or prescription drug, which is why it is marketed strictly as a research chemical.
Copper is a real consideration, not a theoretical one. Injecting a copper peptide repeatedly adds copper to the body, and people with Wilson's disease, liver conditions, or copper metabolism disorders should avoid it entirely. Signs of excess copper can include nausea, fatigue, and abdominal pain.
- Injection site pain, redness, or swelling
- Headache or lightheadedness shortly after injecting
- Allergic reaction to the peptide or the carrier water
- Unknown long-term effects from repeated subcutaneous use
Anyone considering an AHK-Cu peptide injection protocol should first talk with a licensed healthcare professional, especially if they take medication, are pregnant or breastfeeding, or have any chronic condition. Buying from unverified vendors adds another risk, since purity and actual peptide content vary widely between suppliers.
How AHK-Cu Fits Into a Larger Peptide Stack
Copper peptides are often researched alongside other compounds rather than on their own. Some people look into combinations such as the ghk-cu + tb-500 + bpc-157; glow blend, which groups copper peptides with repair-focused peptides in a single protocol.
Stacking multiplies the uncertainty. A bpc-157 dosage chart by weight tells you nothing about how BPC-157 interacts with a copper peptide, and no study has tested these combinations together in humans.
If you are building a protocol, track each compound separately, note the amount and timing, and change one variable at a time. That approach makes it far easier to identify what is helping and what is causing side effects.
Frequently Asked Questions
What is the typical AHK-Cu dosage per day?
Most informal protocols cite 0.5 mg to 2 mg per day or every other day, with 1 mg being the most common figure. Topical cosmetic products use 1% to 2% concentrations instead. No regulatory agency has approved any AHK-Cu dosage for human use.
How do you reconstitute AHK-Cu for injection?
A common approach is adding 5 mL of bacteriostatic water to a 50 mg vial, which yields a 10 mg/mL solution. On a U-100 insulin syringe, 10 units then equals 1 mg. Always verify the math for your specific vial size and water volume before drawing a dose.
Is AHK-Cu legal and safe to inject?
AHK-Cu is not FDA-approved for human use in the United States and is sold as a research chemical only. Reported side effects include injection site irritation, headache, and lightheadedness. Repeated copper exposure is a concern for people with liver disease or copper metabolism disorders, so medical guidance is important before use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.